Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM study of olmesartan versus atenolol for carotid plaque regression in hypertension
NL-OMON34922Phase 4Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypertension (HTN) and atherosclerosis comparing Olmesartan arm with Atenolol arm (2 arms). Primary endpoint: Change in carotid plaque volume from baseline at Week 78. Started Oct 2010; status: active, not recruiting.
02
Drugs
olmesartanatenolol
03
Conditions
hypertension (HTN)atherosclerosis
Beyond the preview
Go deeper on NL-OMON34922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34922.